[Gemcitabine and urogenital tumors].

@article{Culine2002GemcitabineAU,
  title={[Gemcitabine and urogenital tumors].},
  author={St{\'e}phane Culine},
  journal={Bulletin du cancer},
  year={2002},
  volume={89 Spec No},
  pages={S102-6}
}
Among genito-urinary tumors, gemcitabine has only got the marketing approval for advanced urothelial cancer. The combination of gemcitabine and cisplatin has been shown to be a new standard of treatment in this disease because of equal efficacy and lesser toxicity as compared to the classic M-VAC protocol which includes methotrexate, vinblastin, doxorubicin and cisplatin. However new trials are required with the aim of improving survival, especially in the adjuvant setting after cystectomy. The… CONTINUE READING